South San Francisco, CA December 4, 2023 Press Release Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation Phase III (INAVO120) results shows that inavolisib in combination…
South San Francisco, CA October 23, 2020 by Angelique Presidente, ESC Admin Hey South City, Marie Bird, South City native, needs our help. Many of you know her as Marie Smith from going to school throughout the SSFUSD.…
South San Francisco, CA October 3, 2019 Submitted by Angelique Presidente, SSF Resident “Another SSFUSD alum, and long time resident is Battling Cancer Marie needs our help, please share” – Angelique From the GOFUNDME (CLICK HERE) As many of you…
South San Francisco, CA March 8, 2019 Genentech Press Release FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer — This Tecentriq combination is the first cancer immunotherapy regimen approved for breast…
South San Francisco, CA February 8, 2019 Genentech Press Release Genentech Submits Supplemental Biologics License Application to FDA For Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment — Application is being…
South San Francisco, CA October 16, 2018 Press Release Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment — Phase III KATHERINE study shows Kadcyla® significantly improved invasive…
South San Francisco, CA May 10, 2017 Genentech Press Release 20 Genentech medicines are included in more than 190 abstracts during ASCO 2017 New pivotal results for Perjeta® (pertuzumab) and Alecensa® (alectinib) demonstrating improvement over standards of care Early…